330 related articles for article (PubMed ID: 15231725)
1. VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells.
Delgado M; Gonzalez-Rey E; Ganea D
FASEB J; 2004 Sep; 18(12):1453-5. PubMed ID: 15231725
[TBL] [Abstract][Full Text] [Related]
2. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
Delgado M; Reduta A; Sharma V; Ganea D
J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
[TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
Delgado M; Jonakait GM; Ganea D
Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
[TBL] [Abstract][Full Text] [Related]
4. VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells.
Jiang X; Jing H; Ganea D
J Neuroimmunol; 2002 Dec; 133(1-2):81-94. PubMed ID: 12446011
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
Delgado M; Ganea D
J Immunol; 2001 Jul; 167(2):966-75. PubMed ID: 11441105
[TBL] [Abstract][Full Text] [Related]
7. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.
Ganea D; Rodriguez R; Delgado M
Cell Mol Biol (Noisy-le-grand); 2003 Mar; 49(2):127-42. PubMed ID: 12887096
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression.
Delgado M; Leceta J; Gomariz RP; Ganea D
J Immunol; 1999 Oct; 163(7):3629-35. PubMed ID: 10490956
[TBL] [Abstract][Full Text] [Related]
11. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP.
Ganea D; Delgado M
Arch Immunol Ther Exp (Warsz); 2001; 49(2):101-10. PubMed ID: 11348014
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
13. Virus overrides the propensity of human CD40L-activated plasmacytoid dendritic cells to produce Th2 mediators through synergistic induction of IFN-{gamma} and Th1 chemokine production.
Bendriss-Vermare N; Burg S; Kanzler H; Chaperot L; Duhen T; de Bouteiller O; D'agostini M; Bridon JM; Durand I; Sederstrom JM; Chen W; Plumas J; Jacob MC; Liu YJ; Garrone P; Trinchieri G; Caux C; Brière F
J Leukoc Biol; 2005 Oct; 78(4):954-66. PubMed ID: 16081597
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells.
Delgado M; Leceta J; Ganea D
FASEB J; 2002 Nov; 16(13):1844-6. PubMed ID: 12223451
[TBL] [Abstract][Full Text] [Related]
15. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP.
Zusev M; Gozes I
Regul Pept; 2004 Dec; 123(1-3):33-41. PubMed ID: 15518891
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia.
Delgado M
Biochem Biophys Res Commun; 2002 May; 293(2):771-6. PubMed ID: 12054537
[TBL] [Abstract][Full Text] [Related]
18. Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP).
Taupenot L; Mahata SK; Wu H; O'Connor DT
J Clin Invest; 1998 Feb; 101(4):863-76. PubMed ID: 9466982
[TBL] [Abstract][Full Text] [Related]
19. VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression.
Delgado M; Leceta J; Sun W; Gomariz RP; Ganea D
Ann N Y Acad Sci; 2000; 921():68-78. PubMed ID: 11193881
[TBL] [Abstract][Full Text] [Related]
20. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression.
Delgado M; Sun W; Leceta J; Ganea D
J Immunol; 1999 Oct; 163(8):4213-23. PubMed ID: 10510358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
